Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: Described herein are injectable composite inks composed of a hydrogel continuous phase with a plurality of microgels present within the hydrogel continuous phase. The inks described herein have unique chemical and physical properties that enable them to be printed into a number of different types of articles. The articles produced by the injectable composite inks have numerous medical applications.

Abstract: Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, arid intracystic injection.

Abstract: The invention includes saponin-containing compositions, wipes impregnated with these compositions, and related methods. Specifically, the invention includes a cleansing and deodorizing composition that includes a saponin; a deodorizer; cyclodextrin and a solvent. The saponin may be derived from botanical sources, such as, for example, Sapindus mukorossi or trifoliatus. Also included are textiles that are impregnated with the composition of the invention. Such textiles may be, for example, made of biodegradable materials. The invention also includes related methods of use and treatment.

Abstract: The present invention relates to delivery devices adapted to mechanically dilate a pelvic anatomical canal, the delivery devices comprise a composition formulated as a gel comprising a beneficial or therapeutic agent, said delivery devices being capable of releasing the beneficial or therapeutic agent into the pelvic anatomical canal, specifically into the vaginal canal, and thereby treat vaginal conditions associated with vaginal narrowing, atrophy, or dryness.

Abstract: The subject invention pertains to polyacrylate homopolymers produced from acrylolated drug monomers. The homopolymers can be produced in the form of nanoparticles. The nanoparticles comprising the homopolymers can be produced via a free radical-induced emulsion polymerization of the acrylolated drug monomers to produce an aqueous emulsion of uniformly sized nanoparticles. The homopolymers of the invention containing acrylolated antibiotic monomers can be active against Gram-positive and Gram-negative bacteria, such as Staphylococcus aureus and Escherichia coli. Accordingly, methods are provided of treating a disease, for example, an infection, by administering to a subject the homopolymers, homopolymeric nanoparticles, or emulsions containing homopolymeric nanoparticles of the invention.

Abstract: The present invention relates to a particulate nano-lipid carrier for the encapsulation of a bioactive material, and a method for producing same, and more specifically, to a particulate nano-lipid carrier having excellent nanoparticle stability and improved encapsulation of water-soluble drugs. A nano-lipid carrier according to the present invention has significantly improved bioactive material stability and encapsulation efficiency compared to conventional carriers, and it is anticipated that the nano-lipid carrier according to the present invention will be immediately commercializable as a raw material for cosmetics by means of a hair follicle targeting production method suitable for mass production.

Abstract: The present disclosure relates to a method for preparing a haemostatic composition comprising thrombin, the method comprising the step of reconstituting a dry thrombin directly in a paste, such as a paste comprising a biocompatible polymer. The haemostatic composition comprising thrombin may be prepared from a dry thrombin composition and a paste in a single step operation and be used for treatment of a wound.

Abstract: The invention disclosed herein relates to a composition and method of reducing the joint pain associated with hemarthrosis or hemophilic arthropathy. The method includes administering a COX-2 inhibitor, such as rofecoxib, celecoxib, valdecoxib, etoricoxib or other “coxib” drug which is encapsulated in PLGA micro-particles. The COX-2 inhibitor can be administered directly to an area where pain exists by an injection device. In a preferred embodiment, rofecoxib or celecoxib can be encapsulated in PLGA micro-particles for controlled, sustained release over a 2-8-week period. The non-systemic delivery and the controlled, sustained release of rofecoxib alleviate the cardiovascular side effects associated with systemic rofecoxib treatments.

Abstract: The disclosure relates to the treatment and/or prevention of radiation damage by administering a reverse micelle system.

Abstract: A method for treating endometrial cancer comprising: administering to a patient a cannabis extract (CE) wherein the cannabis extract comprises cannabidiol (CBD) at between 50% and 99% by weight of the CE.

Abstract: A protein-modified PLGA microsphere can be used to construct tissue-engineered nerve. The microspheres are loaded with active substances for treating peripheral nerve injury and are bound to tissue-engineered nerves. It has been shown that the prepared tissue-engineered nerve effectively promotes nerve regeneration after peripheral nerve injury.

Abstract: Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators.

Abstract: The present invention relates to a compression bandage for treating wounds comprised of a linear elastic compression wrap and a sterilized polymer foam layer containing a plurality of antimicrobial dyes with at least one dye being gram positive and at least one other dye being gram negative and a biofilm reduction agent and wherein said foam is secured to said linear elastic compression wrap.

Abstract: The present invention relates to a novel pharmaceutical composition of Tamsulosin and Dutasteride and process of manufacture thereof. Specifically, the present invention relates to multiparticulate(s) of Tamsulosin and Dutasteride filled in capsule or/compressed in tablet dosage form and process of manufacture thereof.

Abstract: A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, ethylenediaminedisuccinic acid, an oxidant, water, and optionally citric acid, is provided along with temperature conditions to directly form within the reaction mixture, a stable dispersion of cerium oxide nanoparticles. Biocompatible nanoparticles comprised of cerium oxide, ethylenediaminedisuccinic acid, and optionally citric acid, are described. An increase in catalase-like enzyme activity is demonstrated by cerium oxide nanoparticles prepared with citric acid and ethylenediaminedisuccinic acid.

Abstract: A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

Abstract: Herein is disclosed an elastomeric silicone composition comprising at least a first and a second glycerol phase which are distinct from each other and a method of making the same. The elastomeric compositions are special therein that zero-order active substance release can reversibly be obtained by modifying the glycerol content of the silicone composition.

Abstract: Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.

Abstract: Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.